Kornimate/medical-research-clean huggingface dataset:
effect of vitamin c, d and zinc supplementation on the immune and inflammatory process in type 2 diabetic subjects

Conditions: Diabetes Mellitus, Type 2

Summary: type 2 diabetes mellitus according to the world health organization (who), there are more than 346 million individuals with diabetes, of which 90% are type 2. global estimations for the year 2030 predict an epidemic increase that will reach 366 million. according to the national nutrition and health survey of 2006 (ensanut2005), there are 6.4 million type 2 diabetic subjects in mexico. according to the calculation of the sample size, the investigators will include 120 adults with type 2 diabetes mellitus selected from the outpatient preventive medicine offices of health centres in the state of mexico who will divided in two groups: supplement and placebo (60 per group). after having been invited to participate and obtaining the informed consent, study subjects will be evaluated for dietary information, as well as biochemical biomarkers of metabolic control, anthropometric, immune and inflammatory markers, gut microbiota and oxidative stress, before beginning the trial, and after 12 and 24 weeks of supplementation. they will have a monthly follow-up visit for evaluation of adherence and adverse effects, as well as delivery of the supplement.

subjects will be randomly allocated to a supplementation with 1000 mg vitamin c, 400 iu vitamin d and 10 mg of zinc or placebo group, during 24 weeks. subjects and researchers will be blinded to the supplement or placebo in order to guarantee double-blinding.

Eligibility criteria:
inclusion criteria: * between 25 and 55 years of age, as this is the age in which type 2 diabetes mellitus is more prevalent and there is less probability of encountering multiple diseases in the same subjects * both sexes * outpatients * bmi ≥ 25 exclusion criteria: * without any other chronic disease (cancer, cardiovascular diseases, arthritis and alzheimer's). * severe renal insufficiency. * nephrolithiasis or history of nephrolithiasis. * hyperoxaluria. * hemochromatosis. * hypercalcaemia. * hypervitaminosis d. * using insulin. * be taking drugs such as desferrioxamine, iron, cyclosporine, indinavir (protease inhibitors), warfarin, thiazide diuretic, orlistat, ion exchange resins (e.g cholestyramine, laxatives (e.g. mineral oil, senna), vitamin d analogues (e.g. ergocalciferol, calcitriol, and topical calcipotriene), tetracycline antibiotics, quinolone antibiotics, penicillamine, biphosphonates, levothyroxine, eltrombopag. * patients with hypersensitivity to any of the active substance(s) or to any of the excipients. * hypersensitivity to the by-products including honey, conifers, poplars, peru balsam, and salicylate. * intake of probiotics or supplemental vitamin or mineral (vitamin d, c, zinc or calcium) for 4 weeks before the beginning of the study. * smoking and alcohol consumption (\> 40 gr/ day for men and 25 gr/ day for women. * pregnant or lactating. * whose parents or grandparents are/were immigrant or of native origin.

Keywords: diabetes mellitus type 2 vitamin c vitamin d cinc
topera e-firm registry

Conditions: Atrial Fibrillation

Summary: this is a registry to assess the safety and effectiveness of firm guided procedures for the treatment of symptomatic any type of atrial fibrillation. firm (focal impulse and rotor modulation) guided ablation is defined as ablating rotors identified by the firmap® basket catheter for visualising of rotors with the rhythmview® mapping system. in addition to the firm guided ablation any other ablation method could be applied.the acute success of firm ablations is defined as elimination of rotors defined by absence of rotors. data items will be collected, if available, consistent and applicable with routine and standard clinical care at each participating site.

prospective and retrospective enrollment is possible.

Eligibility criteria:
inclusion criteria: reported incidence of at least 2 documented episodes of symptomatic af (paroxysmal, persistent or long standing persistent) during the 3 months preceding the initial af ablation attempt of at least one class i or iii anti-arrhythmia drug with failure defined as recurrence of symptomatic af or adverse drug effect resulting in stopping medication exclusion criteria: women who are pregnant as this is a registry only data of patients will be included who have been treated according to the current af guidelines.

Keywords: firm procedure
raman spectroscopy diagnosis of kidney diseases

Conditions: IgA Nephropathy (IgAN); Membranous Nephropathy; Diabetic Nephropathy; Focal Segmental Glomerulosclerosis (FSGS)

Summary: this research plan, from january 2021 to december 2024, aims to collect serum and morning urine from patients diagnosed with iga nephropathy, idiopathic membranous nephropathy, diabetic nephropathy, and focal segmental glomerulosclerosis the nephrology department of qianfoshan hospital in shandong province, through renal biopsy. these samples will be scanned using a raman spect to obtain raman spectral data. the scattering peaks in the raman spectra will be analyzed using origin software for gaussian curve fitting. the position of the peaks will used to query relevant literature to identify the corresponding chemical bonds and confirm the presence of compounds. the intensity and area of the chemical substance peaks in the raman will be calculated and used to plot calibration curves, thereby establishing a quantitative analysis equation. this equation will be used to accurately calculate the concentration of each analyte in serum and urine samples. based on the average concentration data for each patient group, multivariate analysis methods, such as principal component analysis (pca) and mahalanis distance discriminant model, will be used to classify and predict the disease types. the preliminary data for this study comes from the nephrology department ofianfoshan hospital, where different types of glomerular diseases have been pathologically classified using tools such as light microscopy, electron microscopy, and immunoforescence microscopy. by combining raman spectroscopy technology and statistical analysis, this study aims to establish a non-invasive and efficient diagnostic tool to assist in the of kidney diseases and predict treatment outcomes.


Eligibility criteria:
inclusion criteria: 1. age 18 years or older; 2. patients diagnosed with iga nephropathy, idiopathic membranous nephrop, diabetic nephropathy, or focal segmental glomerulosclerosis confirmed by renal biopsy; 3. patients who have not received hormone and/or immunosup therapy before the renal biopsy; exclusion criteria: 1. presence of factors causing secondary membranous nephropathy: such as autoimmune diseases (systemic lupus erythematosus),/infections (viral hepatitis), drugs or toxins, etc.; 2. severe infection: clinical manifestations such as fever, cough and sputum, throat, abdominal pain, diarrhea, boils and other skin and soft tissue infections, with white blood cell count in blood routine exceeding the normal range (10×09/l); 3. severe cardiovascular disease: including chronic heart failure of grade 3 or above and various arrhythmias; 4. infect diseases: active phase of various types of hepatitis, aids, syphilis, etc.; 5. evidence of tumor: already diagnosed with a certain tumor or manifestations, tumor markers, etc. indicating the possibility of a tumor; 6. patients with incomplete data or missed diagnosis.
role for biochemical assays and kayser-fleischer rings in diagnosis of wilson disease

Conditions: Wilson Disease

Summary: the investigators aimed to identify factors associated with symptoms and features of wilson disease from a large cohort during long-term follow-up

wilson disease is an autosomal recessive disorder that impairs copper homeostasis and is caused by homozygous or compound heterozygous mutations in atp7b, which encodes a copper-transporting p-type atpase. patients have variable clinical manifestations and laboratory test results, resulting in diagnostic dilemmas. therefore, the investigators aimed to identify factors associated with symptoms and features of wilson disease, thereby give timely diagnosis for patients.

Eligibility criteria:
inclusion criteria: * genetically diagnosed patients with wilson disease exclusion criteria: * deny follow-up
diagnostic performance of an aspergillus-specific nested pcr assay in cerebrospinal fluid samples

Conditions: Focus: Immunocompromised Individuals at High Risk of Aqcuiring Invasive Aspergillosis

Summary: multicentre, diagnostic study evaluating the performance of an aspergillus-specific pcr in cerebrospinal fluid samples of immunocompromised patients for identification of central nervous system aspergillosis.


Eligibility criteria:
inclusion criteria: * host factors * informed consent exclusion criteria: * none
monetary cost of alzheimer's disease in china

Conditions: Alzheimer's Disease

Summary: the purpose of the study is to estimate the chinese economic burden in patients with alzheimer's disease (ad).

this observational study covered all the 30 provincials/municipals/autonomous in mainland china except hong kong and macau. tier 3 hospitals, psychiatric hospitals, elderly hospitals, nursing home and communities were randomly selected as research centers, and more than 2500 patients with ad and their caregivers were enrolled at last. the main outcome of this study was assessed not only by the electronic medical system of communities and hospitals, but also by questionnaires. using a societal prevalence-based gross coi approach to estimated the total yearly costs of ad in china.

Eligibility criteria:
inclusion criteria: 1. new patients who are diagnosed with ad in this investigation or old patients who were diagnosed prior to this investigation were eligible； 2. ad diagnosis must meet criteria of the diagnostic and statistical manual of mental disorders, fourth edition, text revision (dsm-iv-tr) and the national institute of neurologic and communicative disorders and stroke and the alzheimer's disease and related disorders association (nincds-adrda). the diagnosis should also meet the following: modified hachinski ischemic scale (mhis) score≤4, activity of daily living scale (adl) score≥23, geriatric depression scale (gds) score\<11. neuroimaging mri support ad diagnosis (exist atrophy in medial temporal lobe, white matter lesions score≤2 minutes according to the fazekas criteria. ad disease classification according to mini-mental state examination (mmse) scale (for illiterate dementia: mild: 21\~24 points; moderate: 11\~20 points; severe: 10 points or less; for lettered dementia: mild: 16\~19 points; moderate: 8\~15 points; severe: 7 points or less). the diagnosis of ad was confirmed by brain ct or mri scans and by laboratory tests to rule out any other significant comorbidity. 3. 60-year-old and above, men or women. 4. normal vision or corrected visual, normal audition or corrected auditory, and cooperate with inspections and treatments. 5. consent to participate with a signed informed consent by himself/herself or guardians. exclusion criteria: 1. patient with vascular dementia or dementia caused by other reasons, such as major depression or other major psychiatric illnesses, thyroid dysfunction, encephalitis, multiple sclerosis, and other dementia which includes frontotemporal dementia (ftd), dementia with lewy bodies (dlb), and parkinson's dementia (pdd). 2. mri and laboratory tests (blood cell counts, liver and renal function, electrolyte, vitamin b12/folic, hiv, syphilis, and so on) do not support or rule out ad diagnoses. 3. has a history of alcoholism and drug abuse.
an evaluation of cultured milk drink on immune status of patients with irritable bowel syndrome: constipation predominant

Conditions: Irritable Bowel Syndrome With Constipation

Summary: our previous work on the use of probiotics improved the clinical symptoms in irritable bowel syndrome with constipation-predominant. this study would like to explore further use of probiotics in the immune system of the patients with irritable bowel syndrome.

this is a case control study involving participants who fulfilled the rome iii criteria for constipation-predominant irritable bowel syndrome. the patients were recruited from the gastroenterology clinic at universiti kebangsaan malaysia medical centre, kuala lumpur. a total of 165 participants were recruited based on probability (power) of 0.8 and type i error was set at 0.05. the investigators included healthy participants above 18 years old. those less than 18 years old; constipation due to other medical illnesses such as diabetes mellitus, inflammatory bowel disease, hypothyroidism, colorectal cancer, neurological diseases, major depression, lactose intolerance, pregnancy, breastfeeding women and must not be on chronic opioids or anti- depressants were excluded. participants must not consume any antibiotics, probiotic, prebiotic, symbiotic and/or laxatives less than two weeks before recruitment. participants were required to consume three bottles of 125 ml cultured milk drink daily for 30 days. each bottle contains 10\^9 cfu lactobacillus acidophilus la-5 and lactobacillus paracasei l. casei-01. in each 100 ml unit, it contains 4.06 g of fructose, 4.14 g of glucose, 0.29 g of sucrose, less than 0.1 g of maltose and 1.35 g of lactose. cold chain was maintained below 10°c during storage, transportation and distribution. prior to consumption of the cultured milk drinks, fecal and blood samples from the participants were obtained to determine their baseline fecal ph and serum cytokines level respectively. each of the participants answered a food frequency questionnaire to assess their dietary profile (data are not presented in this paper) and the garrigues questionnaire to evaluate their clinical symptoms and physical activity. the same parameters were taken following 30 days of cultured milk drinks' consumption.

Eligibility criteria:
inclusion criteria: * do not fulfil the rome iii criteria for irritable bowel syndrome exclusion criteria: * constipation due to other medical illnesses such as diabetes mellitus, inflammatory bowel disease, hypothyroidism, colorectal cancer, neurological diseases, major depression, lactose intolerance, pregnancy, breastfeeding women and must not be on chronic opioids or anti- depressants. participants must not consume any antibiotics, probiotic, prebiotic, symbiotic and/or laxatives less than two weeks before recruitment.

Keywords: irritable bowel syndrome cultured milk drinks interleukin-6 interleukin-8 tumor necrosis factor-alpha
new assessment system in measuring symptom distress in cancer patients

Conditions: Caregiver; Health Care Provider; Malignant Neoplasm; Physician

Summary: this trial studies how well a new assessment system (mdasi or other md anderson-developed pro instrument) works in measuring symptoms and the impact on quality of life in cancer patients. development of a new assessment system may provide more information about the common symptoms that may occur in patients due to cancer and its treatment and how the symptoms impact quality of life.

primary objectives: i. to examine how the md anderson inventory (md anderson symptom inventory \[mdasi\]) or other md anderson-developed patient reported outcome (pro) instrument performs in various sample populations including community dwelling adults and patients who have different cancer types, who have undergone various treatments, and who have different and/or more severe symptoms. ii. to evaluate the mdasi or other md anderson-developed pro instrument as an estimate of functional status and quality of life. iii. to assess the impact of symptom severity on standard function and health-related quality of life measures, including both quantitative and qualitative measures (patient interviews). iv. to assess the pattern and severity of symptoms over multiple time points in order to assay the system's responsiveness to changes due to therapy or disease. v. to explore the utility of an interactive voice response (ivr) system in enhancing the clinical care of outpatients. vi. to explore the effect of information from an ivr symptom assessment system on the pattern of care and development of interdisciplinary protocols. vii. to explore the feasibility of developing symptom management pathways for patients based on these symptom and quality of life data. outline: participants complete questionnaires and quality of life assessments, and may also complete interviews over 45 minutes periodically.

Eligibility criteria:
inclusion criteria: * normal samples: community dwelling adults 18 years of age or older * patient samples: inpatients and outpatients 18 years of age or older, being followed at ut md anderson * expert panel professional participants: physician or other healthcare provider with at least 5 years of experience caring for patients with the disease and/or treatment of interest, at least one publication in the last 5 years dealing with the disease and/or treatment of interest (physician only), ability to speak and read english, consent to participate * expert panel family caregivers participants: identification as a family caregiver by patient enrolled as expert panel participant with the disease and/or treatment of interest, 18 years of age or older, ability to speak and read english, consent to participate * expert panel patient participants: patient with identified family caregiver participating on expert panel, willingness to receive packet for expert panel participation exclusion criteria: * expert panel patient participants: patient with identified family caregiver participating on expert panel, willingness to receive packet for expert panel participation
lactoferrin versus ferrous fumarate for treatment of mild to moderate iron deficiency anemia during pregnancy

Conditions: Iron Deficiency Anemia of Pregnancy

Summary: this study will conducted to evaluate and comparison between the effectiveness, safety and acceptability of lactoferrin alone, ferrous fumarate alone and combination of both for the treatment of mild to moderate ida during pregnancy.

anemia in pregnancy is a major public health problem, where it has been estimated that 41.8% of pregnant women worldwide are anemic . iron deficiency anemia (ida) is the condition in which there is anemia due to a lack of iron. ida develops when available iron is insufficient to support normal red cell production and is the most common type of anemia anemia has a significant impact on the health of the fetus as well as that of the mother. it impairs the oxygen delivery through the placenta to the fetus and interferes with the normal intrauterine growth, leading to fetal loss and perinatal deaths. anemia is associated with increased preterm labor (28.2%), preeclampsia (31.2%), and maternal sepsis. the daily requirement of iron is around 1.5 mg in nonpregnant women. this requirement increases dramatically during pregnancy to reach 6-7 mg/day (total 1000 mg) with advanced gestational age. pregnancy causes a twofold to threefold increase in the requirement for iron and a 10- to 20-fold increase in folate requirement. the increase in demand for iron is mainly due to fetal requirement, placenta, blood volume, tissue accretion, and the intra-partum potential for blood loss

Eligibility criteria:
inclusion criteria: * pregnant women from 24-36 weeks of gestation. * mild to moderate anemia. exclusion criteria: * women with a history of anemia due to any other causes other than ida. * severe anemia requiring blood transfusion. * history of peptic ulcer. * known hypersensitivity to iron preparations.
phase i study of shr-2002 + shr-1316 in patients with advanced malignant tumors

Conditions: Advanced Malignant Tumors

Summary: this is phase 1 study fih to check "dose escalation, dose expansion and indication expansion". this study is australia only study.


Eligibility criteria:
subjects must meet all the following criteria to be eligible for enrollment into the study: 1. ability to understand and voluntarily agrees to participate by giving written informed consent for the study; 2. male or female aged ≥18 years at the time of signing the icf; 3. histopathologically or cytologically documented advanced or metastatic malignancies and failed or intolerable to previous standard therapy, has no available standard of care therapy or refused standard therapy; 4. an eastern cooperative oncology group (ecog) performance status (ps) score of 0 or 1 (appendix 2); 5. female and male patients of reproductive potential must agree to use highly effective contraception during the study treatment period and within 6 months after the last investigational drug administration. subjects who meet any of the following criteria will be excluded from the study: 1. patients with known active central nervous system (cns) metastases and/or carcinomatous meningitis. 2. patients with tumor-related pain that cannot be controlled as determined by the investigator. 3. systemic anti-tumor therapy within 28 days prior to the first dose of the study treatment 4. history of autoimmune diseases, except for type 1 diabetes (blood glucose can be controlled by insulin therapy) 5. history of clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of study treatment. 6. known history of serious allergic reactions to the investigational product or its main ingredients; 7. history of immunodeficiency, including positive hiv serum test result and other acquired or congenital immunodeficiency diseases, or history of organ transplantation;
arterial endothelial function--an epidemiologic study

Conditions: Cardiovascular Diseases; Heart Diseases; Coronary Arteriosclerosis; Carotid Artery Diseases

Summary: to determine if risk factors measured in childhood can predict the development of atherosclerotic coronary and carotid artery disease in adulthood.

background: many young adult subjects have some degree of atherosclerotic coronary and carotid artery disease and experience no symptoms. as time passes, many die suddenly and unexpectedly and only limited therapeutic process begins in youth, a measure of the early manifestations of atherosclerosis may have the potential of identifying subjects at risk for premature coronary and carotid occlusive vascular disease when therapeutic options can be administered. impaired brachial artery flow mediated dilatory (fmd) capacities have been shown to exist in children and young adults with hypercholesterolemia, hyperhomocysteinemia, diabetes and in those who smoke. impaired brachial artery fmd has been shown to related to impaired endothelial function, which is an early manifestation of the atherosclerotic process. if impaired brachial artery fmd is a predictor of the process, then it may be used to non-invasively assess atherosclerosis early in its development and to evaluate the effect of therapeutic interventions. design narrative: in this longitudinal study using previously studied members of the muscatine study, measurements are made of contemporaneous risk factors, and brachial artery fmd, along with coronary artery calcification (cac) and carotid artery intimal-medial thickness (imt) (the latter two established measures of early atherosclerosis) and again three years later. the effort is designed to examine the following hypotheses: 1) established risk factor levels measured in childhood, adulthood and across the years form childhood through adulthood are predictive of brachial artery flow mediated dilatory (fmd) capacities; 2) putative risk factor levels measured in adulthood are related to the degree of brachial artery fmd, cac and carotid artery imt; 3) brachial artery fmd, cac and carotid artery imtare related in adults; and 4) brachial artery fmd is predictive of increased carotid artery imt.

Eligibility criteria:
participated in at least on school survey examination, at least one young-adult follow-up survey examination and the first longitudinal adult cohort examination